Colistin-resistance gene mcr-1 was detected in an Escherichia coli sample among 442 clinical isolates collected in a tertiary-care hospital in Yangon, Myanmar, in 2018. This isolate was classified into phylogroup A-ST23 complex and harboured bla CTX-M-15 and bla TEM-1 , associated with multiple mutations in quinoloneresistance-determining regions in gyrA and parC.
Colistin (polymyxin E) has been increasingly used worldwide as an antibiotic of last resort for infections caused by carbapenemresistant Gram-negative bacteria. However, since the first report in China in 2016 [1] , occurrence of plasmid-mediated colistin resistance gene mcr-1 has been described in Enterobacteriaceae from animals and humans in Europe, the Americas, Australia and Asia [2] . In Myanmar, mcr-1 has not yet been reported, although this gene has been detected in most of its neighbouring countries.
For the surveillance of carbapenem-resistant Enterobacteriaceae, a total of 1555 clinical isolates were collected at the North Okkalapa General Hospital, Yangon, Myanmar, from January to October 2018 (Supplementary Table S1 ). Among a total of 442 isolates of Escherichia coli, 57 isolates (12.9%) were judged to be resistant to carbapenems by the disc diffusion test and were further analysed for the presence of mcr genes by PCR as described previously [3] . As a result, mcr-1 was detected in only one isolate (MMR-CR4) derived from a urine sample of a 68-year-old female inpatient with a urinary tract infection. MMR-CR4 was resistant to multiple classes of antimicrobials, including quinolone (levofloxacin), but was susceptible to fosfomycin and tigecycline (Table 1, Supplementary  Table S2 ). This isolate was judged to be resistant to ertapenem and colistin with low minimum inhibitory concentrations, but showed susceptibility to imipenem and meropenem.
E. coli isolate MMR-CR4 was classified into phylogenetic group A, single-locus variant of sequence type (ST) 90 (ST23 complex) and fimH subtype 142. Presence of mcr-1, bla CTX-M-15 and bla TEM-1 was confirmed by determination of sequences (GenBank accession nos. MK405590-MK405592), although no carbapenemase gene was detected. This isolate harboured two aminoglycoside-modifying enzyme genes and two plasmidmediated quinolone resistance genes. In the quinolone- resistance-determining region of gyrA and parC, two and one mutations were detected, respectively. In this study, mcr-1 was detected in E. coli for the first time in Myanmar, with a low prevalence among carbapenem-resistant isolates (1/57, 1.8%), which was comparable to those reported for sporadic human cases in other countries [2, 4] . The isolate MMR-CR4 harboured no carbapenemase gene, but it was a carbapenem-resistant Enterobacteriaceae showing multiple-drug resistance. Although ST23 complex has been scarcely identified among E. coli harbouring mcr-1 in humans and animals [5, 6] , only ST410 (ST23 complex) was described in mcr-1-positive clinical isolates in China [7] .
We recently reported that phylogroup A/ST23 complex was a common lineage of E. coli in Myanmar [8] and Bangladesh [9] , and some clones had carbapenemase genes such as bla NDM-1 . Furthermore, ST23 complex, represented by ST90 and ST410, was described as one of the major lineages of carbapenemaseproducing E. coli in Europe, and the origin of a portion of isolates was suspected to be South Asian or Southeast Asian countries [10] . Accordingly, there is a concern that mcr-1-positive, ST23 complex E. coli will acquire the carbapenemase gene, becoming an extremely drug-resistant clone. In addition, MMR-CR4 had multiple mutations in quinoloneresistance-determining regions in gyrA and parC, as identified in Austria [11] , thus suggesting its selective increase with the use of quinolones. Despite its low prevalence, the presence of mcr-1 in a clinical isolate in Myanmar should be noted as sign of spread of multidrug resistance in Enterobateriaceae.
